Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Khiron Life Sciences Corp V.KHRN.H

Alternate Symbol(s):  KHRNF | KHRWF | V.KHRN.WT.H

Khiron Life Sciences Corp. is a Canada-based medical cannabis company with core operations in Latin America. The Company has its wholly owned medical health clinics and telemedicine platforms. The Company has two product lines: Medical Cannabis Products and Health Services. It sells branded medical cannabis products to patients with medical conditions. Under the Medical Cannabis Products line, the Company is focused on product sales in Latin America. The Company operates its own network of health centers (operating under the Zerenia brand) and Zerenia satellite clinics offering a suite of health, medical and surgical services, in alignment with both insurance company partners and private practice. Its subsidiaries include Khiron Life Sciences Corp. (Canada), Khiron Colombia S.A.S., Zerenia S.A.S., NettaGrowth International Inc., and others.


TSXV:KHRN.H - Post by User

Comment by RoadRunner123on Feb 13, 2020 12:44pm
250 Views
Post# 30686616

RE:RE:RE:UM ... 45 milion in cash and 77 M market cap = Way Oversold

RE:RE:RE:UM ... 45 milion in cash and 77 M market cap = Way OversoldLooks like from last quarterly numbers and the Canaccord report for the quarter that the cash burn is being managed and reduced. I would expect this trend to continue as management streamlines activities and refocuses on core business activities. This company is now at an all-time low in terms of share price as a public company yet has a more advanced business and stronger cash position than at any point during its history. The key catalyst will commencing medical sales – where Khiron will likely be one of the first companies to sell product in Colombia. We see some sales numbers ramp and management of cash burn, I believe your predictions are extremely low. Time will tell, but this company is certainly in much better position than others. GLTA.

Do you own DD. 
<< Previous
Bullboard Posts
Next >>